Monckeberg Medial Calcific Sclerosis
Conditions
Keywords
Athletes, Sedentary volunteers
Brief summary
The main objective of this study is to obtain data for the integrated analysis of morphological, functional and biomechanical parameters pertaining to lower limb arteries in various categories of elite athletes (without cardiovascular risk and practicing high- or low-impact aerobic activities which preferentially implicate lower limb activity) as compared to (each other and to) sedentary controls.
Detailed description
Secondary objectives of this study are: A. Determine the presence and extent of intima-media calcifications in athletes B. Determine the relationship between these calcifications and the level, length and intensity of sports activity. C. Determine the relationship between these properties and calcification of the arterial wall D. Analyze the relationship between the type of sports activity and properties of the arterial wall. E. Examine the relationship between the properties of the arterial wall and peripheral perfusion pressures. F. Examine the relationship between the properties of the arterial wall, changes in afterload, morphology and systolic heart function. G. Analyze the relationships between the parameters characterizing the arterial wall and muscle mass of the lower limbs. H. Analyze the relationship between the presence of intramural calcification and bone density determined by densitometry. I. Analyze the relationship between the presence of intramural calcification and dietary protein intake and calcium. J. Compare indices of pressure at the ankle and toe, depending on the extent of calcification. K. Create a collection of biological samples (serum).
Interventions
None listed
Sponsors
Centre Hospitalier Universitaire de Nīmes
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
25 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
for athletic and sedentary volunteers: * The volunteer must have given his/her informed and signed consent * The volunteer must be insured or beneficiary of a health insurance plan * Volunteers without cardiovascular disease, glucose regulation disorders or known renal disease Inclusion Criteria for athletic volunteers only: * Ongoing athletic activity for the past 10 years * Athletic activity at the regional level for the past 5 years * Practices one of the three following sports: marathon, trail running, cycling.
Exclusion criteria
for athletic and sedentary volunteers: * The volunteer is participating in another study * The volunteer is in an exclusion period determined by a previous study * The volunteer is under judicial protection, under tutorship or curatorship * The volunteer refuses to sign the consent * It is impossible to correctly inform the volunteer * The volunteer is pregnant, parturient, or breastfeeding * Tobacco use * Contraindications for the practice of physical activity (joint, heart or other) * Intercurrent pathology * First degree family history of cardiovascular disease * Known dyslipidemia (including cholesterol) * Glucose tolerance abnormalities (prediabetes or diabetes) * Treatment with certain drugs used for treating erectile dysfunction: Sildefanil (Viagra), Tadalafil (Cialis), Vardenafil (Levitra) and yohimbine (Yohimbine Houde and Yocoral)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Presence / absence of intra parietal calcification of lower limb arteries | Baseline (Day 0; transversal study) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Inner diameter of the intima-media of the common femoral artery (mm) | Baseline (Day 0; transversal study) | — |
| Outer diameter of the intima-media of the common femoral artery (mm) | Baseline (Day 0; transversal study) | — |
| Inner diameter of the intima-media of the superficial femoral artery (mm) | Baseline (Day 0; transversal study) | — |
| Outer diameter of the intima-media of the superficial femoral artery (mm) | Baseline (Day 0; transversal study) | — |
| Inner diameter of the intima-media of the common carotid artery (mm) | Baseline (Day 0; transversal study) | — |
| Outer diameter of the intima-media of the common carotid artery (mm) | Baseline (Day 0; transversal study) | — |
| Thickness of the intima-media of the common femoral artery (mm) | Baseline (Day 0; transversal study) | — |
| Thickness of the intima-media of the superficial femoral artery (mm) | Baseline (Day 0; transversal study) | — |
| Thickness of the intima-media of the common carotid artery (mm) | Baseline (Day 0; transversal study) | — |
| Local parietal compliance of the superficial femoral artery | Baseline (Day 0; transversal study) | mm\^2/mmHg |
| Compliance of the carotid artery | Baseline (Day 0; transversal study) | mm\^2/mmHg |
| Distensibility of the carotid artery | Baseline (Day 0; transversal study) | mmHg\^-1\*10\^-2 |
| Arterial wave velocity in lower limb | Baseline (Day 0; transversal study) | m/s |
| Arterial wave velocity in upper limb | Baseline (Day 0; transversal study) | m/s |
| Endothelium-dependent vasorelaxation in the femoral artery | Baseline (Day 0; transversal study) | — |
| Postischemic vasomotor response at the (skin) microcirculatory level | Baseline (Day 0; transversal study) | — |
| Systolic pressure index at the ankle | Baseline (Day 0; transversal study) | relative units |
| Systolic pressure index for the big toe | Baseline (Day 0; transversal study) | relative units |
| Cardiac afterload index | Baseline (Day 0; transversal study) | g/cm\^2 |
| Echocardiographic parameters analyzing systolic function: the stroke volume | Baseline (Day 0; transversal study) | ml |
| Echocardiographic parameters analyzing systolic function: cardiac output | Baseline (Day 0; transversal study) | l/min |
| Echocardiographic parameters analyzing systolic function: peripheral vascular resistance | Baseline (Day 0; transversal study) | Pa.s/m\^3 |
| Echocardiographic parameters analyzing systolic function: fractional shortening | Baseline (Day 0; transversal study) | — |
| Echocardiographic parameters analyzing systolic function: speed of the S-wave according to tissue Doppler | Baseline (Day 0; transversal study) | cm.s-1 |
| Echocardiographic parameters analyzing systolic function: global longitudinal strain | Baseline (Day 0; transversal study) | — |
| Ventricular-arterial coupling | Baseline (Day 0; transversal study) | relative units |
| Echocardiographic parameters analyzing diastolic function: transmitral E wave velocity | Baseline (Day 0; transversal study) | cm/s |
| Echocardiographic parameters analyzing diastolic function: transmitral A wave velocity | Baseline (Day 0; transversal study) | cm/s |
| Echocardiographic parameters analyzing diastolic function: transmitral E wave velocity / transmitral A wave velocity | Baseline (Day 0; transversal study) | relative units |
| Echocardiographic parameters analyzing diastolic function: maximum Em wave velocity according to tissue Doppler | Baseline (Day 0; transversal study) | cm/s |
| Echocardiographic parameters analyzing diastolic function: maximum Am wave velocity according to tissue Doppler | Baseline (Day 0; transversal study) | cm/s |
| Echocardiographic parameters analyzing diastolic function: transmitral E wave velocity / maximum Em wave velocity according to tissue Doppler | Baseline (Day 0; transversal study) | relative units |
| Echocardiographic parameters analyzing diastolic function: early diastolic strain-rate | Baseline (Day 0; transversal study) | s\^-1 |
| Years of athletic training | Baseline (Day 0; transversal study) | — |
| Hours of athletic training per week | Baseline (Day 0; transversal study) | h/week |
| Best performance in the last 6 months | Baseline (Day 0; transversal study) | — |
| Lower limb muscle mass | Baseline (Day 0; transversal study) | g |
| Bone density | Baseline (Day 0; transversal study) | g/cm\^2 |
| Dietary protein intake | Baseline (Day 0; transversal study) | g/day |
| Dietary calcium intake | Baseline (Day 0; transversal study) | mg/day |
| Extent of intra parietal calcification of lower limb arteries | Baseline (Day 0; transversal study) | Score ranging from 0 to 3 |
| Serum calcium | Baseline (Day 0; transversal study) | mmol/l |
| Serum phosphorus | Baseline (Day 0; transversal study) | mmol/l |
| Serum parathyroid hormone | Baseline (Day 0; transversal study) | ng/l |
| Serum vitamin D2 | Baseline (Day 0; transversal study) | µg/l |
| Serum vitamin D3 | Baseline (Day 0; transversal study) | µg/l |
| Serum protein | Baseline (Day 0; transversal study) | g/l |
Countries
France
Outcome results
None listed